Scottish Medicines Consortium (SMC) To Accept Baraclude® (entecavir) For Use Within NHS For The Treatment Of Hepatitis B
Bristol-Myers Squibb Pharmaceuticals Limited (Bristol-Myers Squibb) has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Baraclude® (entecavir) for use within NHS Scotland for the treatment of chronic hepatitis B virus infection. [click link for full article]
posted by Smile Community @ 9:09 PM
0 Comments:
Post a Comment
<< Home